Table 5. Univariate and Multivariate Analysis for Survival After HMA Failure.
| TFS | OS | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| UVA | MVA | UVA | MVA | |||
|
| ||||||
| Parameter | P | HR | P | P | HR | P |
| Platelets <100 × 109/L | <.001 | NA | NS | <.001 | NA | NS |
| BM blasts >5% | <.001 | NA | NS | <.001 | NA | NS |
| CG-IPSS: int/poor | <.001 | NA | NS | <.001 | NA | NS |
| IPSS: higher risk | <.001 | NA | NS | <.001 | NA | NS |
| IPSS-R higher risk | <.001 | NA | NS | <.001 | NA | NS |
| MDGSS: higher risk | <.001 | 1.5 | .003 | <.001 | 1.8 | .002 |
| LRMDSS: higher risk | <.001 | NA | NS | <.001 | NA | NS |
| Lack of response to HMA | <.001 | NA | NS | .002 | NA | NS |
| Salvage therapy | NS | NA | NA | .001 | 0.8 | .01 |
Abbreviation: BM, bone marrow; CG, cytogenetic; HMA, hypomethylating agent; HR, hazards ratio; int, intermediate; IPSS, International Prognostic Scoring System; IPSS-R, revised International Prognostic Scoring System; LRMDSS, Low-Risk MD Anderson Scoring System; MDGSS, The University of Texas MD Anderson Global Scoring System; MVA, multivariate analysis; NA, not applicable; NS, not significant; OS, overall survival; TFS, transformation-free survival; UVA, univariate analysis.